Marc Suárez-Calvet, MD, PhD, Barcelonaβeta Brain Research Center (BBRC), Barcelona, Spain, discusses the ongoing search for plasma biomarkers that accurately detect preclinical Alzheimer’s disease (AD). Findings from Dr Suárez-Calvet’s lab and others suggest that plasma phosphorylated tau-231 (p-tau231) detects amyloid pathology earlier than other p-tau biomarkers. It is thought that plasma p-tau levels may be useful as pre-screening tools to identify patients at-risk groups in the very earliest stages, in order to enrich clinical trial populations. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.

свернуть